Delivery Order SPE2DB22D3016-SPE2DB25FAUP7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,417.22 to AmerisourceBergen Drug Corp for Rexulti 2 mg tablets (30-count package) on September 25, 2025, with an ultimate completion date of September 26, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $1,278.42 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $11,846.76 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical delivery order and functions as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,846.60 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count package). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Rexulti 2 mg tablets (quantity: 30 units) with a ceiling value of $2,927.61. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $3,032.03 to AmerisourceBergen Drug Corp on May 2, 2025, for the supply of Rexulti 3 mg tablets (30-count). The award is a firm fixed-price, non-competitive delivery order with a completion date of May 5, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $10,036.57 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 26, 2025, with an ultimate completion date of August 27, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery order from its Conshohocken facility. This...
- The Defense Logistics Agency awarded a $10,676.55 delivery order to AmerisourceBergen Drug Corp for 30 tablets of Rexulti 1 mg on September 5, 2025, with a completion date of September 8, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where the vendor maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, valued at $18,081.18, for 30-count tablets of Rexulti 1 mg on September 15, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a single transaction under the company's broader pharmaceutical supply relationship with the federal government. The product will be delivered to AmerisourceBergen's...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FAUP7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,608.75 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count packaging) on April 23, 2025, with completion scheduled for April 24, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical transaction under the company's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is a child contract executed under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical federal vendor for military and veteran healthcare systems, AmerisourceBergen regularly fulfills federal medical procurement needs across diverse therapeutic domains through competitively awarded delivery orders with firm fixed pricing. The supply of Rexulti, an antipsychotic medication, supports DLA's mission to provision pharmaceutical products for military healthcare programs and other authorized federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.6k | 4/23/25 |